Baillie Gifford & Co. raised its position in ABIOMED, Inc. (NASDAQ:ABMD) by 2.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 588,171 shares of the company’s stock after buying an additional 12,928 shares during the period. Baillie Gifford & Co. owned 1.35% of ABIOMED worth $66,274,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Calvert Investment Management Inc. increased its stake in shares of ABIOMED by 0.9% in the second quarter. Calvert Investment Management Inc. now owns 2,242 shares of the company’s stock worth $245,000 after buying an additional 20 shares during the period. Balasa Dinverno & Foltz LLC increased its stake in shares of ABIOMED by 0.9% in the third quarter. Balasa Dinverno & Foltz LLC now owns 3,948 shares of the company’s stock worth $508,000 after buying an additional 34 shares during the period. RMB Capital Management LLC increased its stake in shares of ABIOMED by 0.4% in the third quarter. RMB Capital Management LLC now owns 10,240 shares of the company’s stock worth $1,317,000 after buying an additional 40 shares during the period. WFG Advisors LP increased its stake in shares of ABIOMED by 0.7% in the second quarter. WFG Advisors LP now owns 7,581 shares of the company’s stock worth $829,000 after buying an additional 51 shares during the period. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its stake in shares of ABIOMED by 0.9% in the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 5,973 shares of the company’s stock worth $673,000 after buying an additional 53 shares during the period. Institutional investors own 92.67% of the company’s stock.

Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

ABIOMED, Inc. (NASDAQ:ABMD) traded up 3.28% during midday trading on Thursday, reaching $114.25. The company’s stock had a trading volume of 725,334 shares. The firm has a market cap of $4.96 billion, a P/E ratio of 106.88 and a beta of 0.51. The firm has a 50 day moving average price of $110.97 and a 200 day moving average price of $116.57. ABIOMED, Inc. has a one year low of $78.46 and a one year high of $132.95.

ABIOMED (NASDAQ:ABMD) last issued its quarterly earnings data on Thursday, January 26th. The company reported $0.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.29 by $0.05. ABIOMED had a net margin of 11.63% and a return on equity of 12.35%. The firm earned $114.70 million during the quarter, compared to the consensus estimate of $112.71 million. During the same quarter in the previous year, the firm posted $0.23 EPS. The company’s revenue for the quarter was up 33.1% compared to the same quarter last year. Equities research analysts forecast that ABIOMED, Inc. will post $1.18 EPS for the current fiscal year.

This piece was published by Watch List News and is the property of of Watch List News. If you are reading this piece on another site, it was illegally stolen and republished in violation of United States and international copyright law. The original version of this piece can be read at http://www.watchlistnews.com/abiomed-inc-abmd-stake-raised-by-baillie-gifford-co/1121015.html.

ABMD has been the topic of a number of research reports. BTIG Research restated a “buy” rating and set a $170.00 price target on shares of ABIOMED in a research report on Sunday, January 8th. Zacks Investment Research downgraded ABIOMED from a “hold” rating to a “sell” rating in a research report on Thursday, January 5th. Guggenheim initiated coverage on ABIOMED in a research report on Tuesday, December 6th. They set a “buy” rating and a $150.00 price target on the stock. Finally, TheStreet downgraded ABIOMED from a “buy” rating to a “hold” rating in a research report on Thursday, October 27th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $146.83.

In other news, Director Dorothy E. Puhy sold 8,000 shares of the business’s stock in a transaction on Tuesday, December 13th. The shares were sold at an average price of $120.00, for a total transaction of $960,000.00. Following the completion of the sale, the director now owns 32,749 shares of the company’s stock, valued at approximately $3,929,880. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 10.00% of the company’s stock.

ABIOMED Company Profile

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

5 Day Chart for NASDAQ:ABMD

Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ABIOMED, Inc. (NASDAQ:ABMD).

Receive News & Ratings for ABIOMED Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.